According to a new report published by Allied Market Research, titled, “Global HIV Drugs Market by Medication Class and Region: Global Opportunity Analysis and Industry Forecast, 2020–2027.” The global HIV drugs market accounted for $30.89 billion in 2019, and is expected to reach $36.49 billion by 2027, registering a CAGR of 3.8% from 2020 to 2027.

Human immunodeficiency virus (HIV) is one of the most challenging infectious diseases that affected around 39.6 million people globally by the end of 2018, according to the Joint United Nations Program on HIV/AIDS (UNAIDS). Antiretroviral Therapy (ART) drugs are used for the treatment of HIV as they prevent the growth of the HIV virus.

Download Report Sample with Industry Insights @

The major factors that boost the growth of the market include increase in prevalence of HIV globally and rise in treatment & diagnosis rate. In addition, there is escalation in government initiatives to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Therefore, raising awareness through such government initiatives is expected to drive the HIV drugs market growth.

The global HIV drugs market is bifurcated on the basis of medication class and region. On the basis of medication class, the market is segmented into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, and HIV integrase strand transfer inhibitors. In the medication class, the multi-class combination drugs segment holds the largest market share as it involves the most advanced technique used for the treatment of HIV infection.

Request for Customization @

Prominent players operating in the HIV Drugs market include, Boehringer Ingelheim International GmbH, Merck & Co., Inc., GalaxoSmithKline plc. AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Gilead Sciences, Inc., Johnson & Johnson, and Cipla Limited

Key findings of the study

  • North America accounted for 48.40% market share in 2019, and is expected to maintain this trend over the forecast period.
  • On the basis of medication class, the multi-class combination drugs segment is anticipated to grow at a CAGR of 4.1% from 2020 to 2027.
  • The Asia-Pacific HIV drugs market is estimated to grow at a CAGR of 4.4% during the forecast period.


Q1. What is the market value of HIV Drugs Market report in forecast period?

Q2. What would be forecast period in the market report?

Q3. What is the market value of HIV Drugs Market in 2020?

Q4. Which is base year calculated in the HIV Drugs Market report?

Q5. Does the HIV Drugs Market Company is profiled in the report?

Q6. Which are the top companies hold the market share in HIV Drugs Market?

Q7. Does the HIV Drugs Market report provides Value Chain Analysis?

Q8. What are the key trends in the HIV Drugs Market report?

Inquire before Buying:

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.


David Correa

5933 NE Win Sivers Drive

#205, Portland, OR 97220

United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975


Leave a comment

Your email address will not be published. Required fields are marked *